Senti Biosciences Inc.
04/01/2026 | Press release | Distributed by Public on 04/01/2026 14:32
Material Event (Form 8-K)
Item 8.01 Other Events
On April 1, 2026, Senti Biosciences, Inc. (the "Company") announced plans to implement a holding company reorganization (the "Holding Company Reorganization"), currently planned to become effective by April 16, 2026, by executing a tax-free merger of the Company with and into Senti Biosciences Merger Sub, Inc., a newly formed Delaware corporation that is a subsidiary of a newly formed Delaware corporation, Senti Holdings, Inc. ("Senti Holdings"). Senti Holdings is a subsidiary of a newly formed Delaware corporation, Senti Biosciences Holdings, Inc. ("Senti Biosciences Holdings"), which is a wholly owned subsidiary of the Company. Upon the effectiveness of the Holding Company Reorganization, Senti Biosciences Holdings would become the successor issuer to the Company.
Each share of the Company's common stock, par value $0.0001 per share ("Company Common Stock"), issued and outstanding immediately prior to the Holding Company Reorganization would automatically be converted into an equivalent corresponding share of Senti Biosciences Holdings' common stock, par value $0.0001 per share ("Holdings Common Stock"), having the same designations, rights, powers and preferences and the qualifications, limitations and restrictions as the corresponding share of Company Common Stock being converted.
Accordingly, upon consummation of the Holding Company Reorganization, the Company's stockholders immediately prior to the consummation of the Holding Company Reorganization would become stockholders of Senti Biosciences Holdings. The stockholders of the Company would not recognize gain or loss for U.S. federal income tax purposes upon the conversion of their shares of Company Common Stock in the Holding Company Reorganization.
The Holding Company Reorganization would be conducted pursuant to Section 251(g) of the General Corporation Law of the State of Delaware, which provides for the formation of a holding company without a vote of the stockholders of the constituent corporation. The conversion of stock would occur automatically without any action on the part of existing securityholders. Immediately after the Holding Company Reorganization, stock certificates and book-entries that previously represented shares of Company Common Stock would represent the same number of shares of the corresponding shares of Holdings Common Stock. Following the consummation of the Holding Company Reorganization, Holdings Common Stock would continue to trade on the Nasdaq Capital Market on an uninterrupted basis under the symbol "SNTI" with a new CUSIP number. Immediately after consummation of the Holding Company Reorganization, Senti Biosciences Holdings would have, on a consolidated basis, the same directors, assets, businesses and operations as the Company had immediately prior to the consummation of the Holding Company Reorganization. The directors of Senti Biosciences Holdings and their committee memberships and titles would be the same as the directors of the Company immediately prior to the Holding Company Reorganization. The executive officers and officers of Senti Biosciences Holdings would be the same as the executive officers and officers, respectively, of the Company immediately prior to the Holding Company Reorganization, with the same title, duties and responsibilities.
The Company may determine not to implement the Holding Company Reorganization or the completion of the Holding Company Reorganization could be delayed beyond the currently anticipated timeframe, including for factors beyond the control of the Company.
Senti Biosciences Inc. published this content on April 01, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on April 01, 2026 at 20:33 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]